419 related articles for article (PubMed ID: 27263792)
1. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
3. [Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
Hattori H; Kuwayama M; Takamori H; Nishiura N; Karasuno T
Rinsho Ketsueki; 2014 Dec; 55(12):2429-32. PubMed ID: 25744045
[TBL] [Abstract][Full Text] [Related]
4. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
5. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
11. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.
Gardellini A; Guidotti F; Feltri M; Zancanella M; Maino E; Ambrosiani L; Turrini M
Blood Cells Mol Dis; 2021 Dec; 92():102620. PubMed ID: 34715450
[TBL] [Abstract][Full Text] [Related]
13. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
17. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
